Abstract Library

#3313 Carcinoid heart surgery: Review of outcomes from a single large centre

Introduction: Up to half of patients with carcinoid syndrome develop carcinoid heart disease and valve degeneration can lead to right heart failure. Surgical replacement of affected valves is an effective therapy. Peptide receptor radio-targeted therapy (PRRT) has demonstrated better progression-free survival compared to high dose sandostatin LAR.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Maclean R

Authors: Maclean R, Cope J, Hota S, Mulholland N, Ramage J,

Keywords: PRRT, Lutetium, Lutathera, carcinoid syndrome, valve replacement,

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy

Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hota S, Cananea E, Martin W, Clement D, Solis B,

Keywords: Neuroendocrine tumours, carcinoid syndrome, telotristat ethyl,

#2806 Sarcopenia: Don't Judge a Book by It's Cover

Introduction: Sarcopenia is characterised by loss of muscle mass and function. We previously reported anthropometrical data for a range of NET diagnoses within 3 months of diagnosis. The majority of NET patients were overweight or obese, however reduced muscle function was observed in over half of patients regardless of BMI and other parameters.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Whyand T, Chotai de Lima Y, Caplin M,

Keywords: Neuroendocrine neoplasm, nutrition, dietitian, sarcopenia,